AstraZeneca PLC is 169.4x more valuable than MBX Biosciences, Inc. by market capitalization ($286.27 B vs $1.69 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | MBX | AZN |
|---|---|---|
| Market cap | $1.69 B | $286.27 B |
| US-listed rank | #2238 | #49 |
| Net income (latest FY) | -$87.00M | - |
| SEC filings | 198 | 1,004 |
AstraZeneca PLC is 169.4x more valuable than MBX Biosciences, Inc. by market capitalization ($286.27 B vs $1.69 B).
Full pages: MBX Biosciences, Inc. and AstraZeneca PLC, or browse the full rankings.